Gi­ant Roche wades in­to the pre­clin­i­cal NL­RP3 pool, bag­ging Je­cure for their an­ti-in­flam­ma­to­ry team at Genen­tech

You can now count the bio­phar­ma gi­ant Roche among the grow­ing num­ber of play­ers fas­ci­nat­ed by the po­ten­tial of NL­RP3 in­hi­bi­tion.

Their big Cal­i­for­nia sub­sidiary Genen­tech has snapped up a lit­tle San Diego-based biotech called Je­cure Ther­a­peu­tics, which came out of qui­et time with a $20 mil­lion launch round from Ver­sant and a big ap­petite for NASH re­search. The ven­ture group had been drawn in by an ex­pe­ri­enced biotech team that had built and sold Quan­ti­cel to Cel­gene for close to $485 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.